Laboratory Medicine ›› 2021, Vol. 36 ›› Issue (10): 1094-1096.DOI: 10.3969/j.issn.1673-8640.2021.010.022
Received:2020-12-18
Online:2021-10-30
Published:2021-11-08
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2021.010.022
| [1] |
SEHN L H, GASCOYNE R D. Diffuse large B-cell lymphoma:optimizing outcome in the context of clinical and biologic heterogeneity[J]. Blood, 2015, 125(1):22-32.
DOI URL |
| [2] | 杨融辉, 廖爱军. 伴浆细胞分化的弥漫大B细胞淋巴瘤一例病例报告并文献复习[J]. 实用药物与临床, 2018, 21(6):680-682. |
| [3] |
KORKOLOPOULOU P, VASSILAKOPOULOS T, MILIONIS V, et al. Recent advances in aggressive large B-cell lymphomas:a comprehensive review[J]. Adv Anat Pathol, 2016, 23(4):202-243.
DOI URL |
| [4] |
HU S, XU-MONETTE Z Y, BALASUBRAMANYAM A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature:a report from the International DLBCL Rituximab-CHOP Consortium Program Study[J]. Blood, 2013, 121(14):2715-2724.
DOI URL |
| [5] |
TERAS L R, DESANTIS C E, CERHAN J R, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes[J]. CA Cancer J Clin, 2016, 66(6):443-459.
DOI URL |
| [6] |
ALIZADEH A A, EISEN M B, DAVIS R E, et al. Distinct types of diffuse large B-cell lymphoma identifified by gene expression profiling[J]. Nature, 2000, 403(6769):503-511.
DOI URL |
| [7] |
HANS C P, WEISENBURGER D D, GREINER T C, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray[J]. Blood, 2004, 103(1):275-282.
DOI URL |
| [8] |
BRUDNO J, TADMOR T, PITTALUGA S, et al. Discordant bone marrow involvement in non-Hodgkin lymphoma[J]. Blood, 2016, 127(8):965-970.
DOI URL |
| [9] | 仲凯励, 黄小会, 王玉涵, 等. 去泛素化酶MYSM1调控人B细胞向浆细胞的分化[J]. 中国实验血液学杂志, 2019, 27(5):1627-1632. |
| [10] |
DEVIN J, KASSAMBARA A, BRUYER A, et al. Phenotypic characterization of diffuse large B-cell lymphoma cells and prognostic impact[J]. J CLin Med, 2019, 8(7):1047.
DOI URL |
| [11] | 赵佳莉, 罗茜, 张敏. 弥漫大B细胞淋巴瘤组织中LncRNA TP73-AS1的检测水平及临床意义[J]. 西部医学, 2020, 32(10):1517-1520. |
| [12] |
WIGHT J C, CHONG G, GRIGG A P, et al. Prognostication of diffuse large B-cell lymphoma in the molecular era:moving beyond the IPI[J]. Blood Rev, 2018, 32(5):400-415.
DOI URL |
| [13] | 张艳, 唐勇, 姚一芸, 等. 头颈部弥漫大B细胞淋巴瘤患者临床特征及预后模型分析研究[J]. 中国癌症杂志, 2020, 30(6):449-455. |
| [14] |
PFREUNDSCHUH M, TRÜMPER L, OSTERBORG A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B cell lymphoma:a randomised controlled trial by the MabThera International Trial(MInT) Group[J]. Lancet Oncol, 2006, 7(5):379-391.
DOI URL |
| [15] | 郑文帅, 管立勋, 程龙灿, 等. 复发/难治性弥漫大B细胞淋巴瘤患者的临床特征及预后分析[J]. 中国实验血液学杂志, 2020, 28(5):1551-1557. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
